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Introduction: Lower Urinary Tract symptoms (LUTS)? impacts the quality of life of 
about 23.8% of the male population in Iran, diagnosed with Benign Prostatic 
Hyperplasia, annually . The current pharmacological treatment protocol for LUTS 
are α-blockers and 5-alpha reductase inhibitors (such as Dutasteride). This study was 
designed to estimate the cost-utility of dutasteride plus tamsulosin therapy for LUTS 
from the perspective of the Iran Health System. 
Methods and Results: A Markov model was developed to estimate healthcare costs 
and patient outcomes, measured by quality-adjusted life years (QALYs), for patients 
with moderate to severe LUTS. The model, compared four mutually exclusive health 
states in two alternative treatment options: tamsulosin (0.4 mg/day) and dutasteride 
plus tamsulosin (0.5mg+0.4 mg/day). time horizon was 35 years, with the duration of 
one year per cycle. The discount rates for utilities and costs were 3% and 5% 
respectively. A meta-analysis was conducted to estimate advese drug reactions 
(ADRs) and After Surgery Events (ASEs) probabilities. Total Cost consists of the 
direct costs of medications, as well as inpatient and outpatient services (general 
practice and urology specialist examinations, hospitalizations, laboratory services, 
diagnostic procedures, TURP surgical procedures, treatment of AUR, and treatment 
in emergency care services). One-way sensitivity testing and Probabilistic Sensitivity 
Analyses (PSA) were performed for virtual cohort of 1,000 patients with LUTS. 
Utility weights for each health states were obtained from a meta-analysis of 
published studies with EQ5D method. These weights are calculated 0.86, 0.79, 0.72 
and 0 in mild, moderate, severe and death states, respectively. The probability of 
ASEs (CI 95%) were calculated as: TUR syndrome (0-0.0109), Blood transfusion 
(0.0296-0.0676), Urinary incontinence (0.0198-0.1894), urethral stricture (0.0392-
0.0769) and UTI (0.0169-0.0787). After 35 years, the incremental cost-effectiveness 
ratio for combination therapy was $5159, well within the threshold range typically 
applied in Iran. PSA showed that the probability of being cost-effective in 
combination therapy is 89% to 94%, also the model showed the most sensitivity to 
dutasteride unit price and surgery incidence with monotherapy. 
Conclusions: Combination therapy has a high probability of being cost-effective in 
comparison to tamsulosin monotherapy in Iran. 
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